TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Willingness to have low SES patients in practice
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Healing rates at week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of noninvasive ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved scalp coverage
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: TUAD increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sST2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: morbid event
Endpoint domain: Mortality/survival
Primary endpoint: NPQ score improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Curative and effective rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuropsychiatric Inventory (NPI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NPI caregiver burden
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Bioavailability of AMPH EROS compared to IR MAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 25(OH)D level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of VD deficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of VD deficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Airway vascular endothelial function (ΔQaw)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Levels of IgA, IgG, CD4+, and CD4+/CD8+
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum albumin, prealbumin, transferrin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ovarian Hyperstimulation Syndrome (OHSS) incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Incident musculoskeletal disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Neck/shoulder pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Right upper extremity pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: 3-dimensional cycle shapes during mastication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postpacing Interval - Tachycardia Cycle Length Difference (PPI-TCL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: sleep quality improvement rate
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: sACE2 plasma activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients with post-extubation cough
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients successfully treated in the second phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time spent in the range 3.9‐10.0 mmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: median post-PD OS
Endpoint domain: Mortality/survival
Primary endpoint: Desire score
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: Arousal score
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: global improvement ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of perineal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severity of perineal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of perineal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of multiple sclerosis
Endpoint domain: Mortality/survival
Primary endpoint: time to first major or clinically relevant non-major bleeding events
Endpoint domain: Adverse events/effects
Primary endpoint: Positive resection margins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: VMMC uptake within 2 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acute gain of SB FFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: late loss of SB FFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: rate of FFR post-stenting > 0.94
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Quit rate at 6 months
Endpoint domain: Mortality/survival
Primary endpoint: Average number of drinks per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum gamma‐glutamyltransferase (GGT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient reactions to pen-tablet computers
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean plasma glucose concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Grade 3-4 non-hematological toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Grade 3-4 hematological toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: TLS of three or less
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of apoptosis in BE1-axin cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proliferative abilities of BE1-axin cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Invasive abilities of BE1-axin cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful IUD insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Duration of extensor coactivation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete recovery rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: macroscopic healing of the fissures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fissure-related pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-efficacy for health promotion activities
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: health promotion activity undertaken
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: quality of life improvements (mental health and general health)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: diuretic intensity of RBUD-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: developing time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Power output in the first kilometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time before overtaking opponent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total fixation time on virtual opponent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of stroke or systemic embolism
Endpoint domain: Mortality/survival
Primary endpoint: Decrease in DUDIT-C scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of clinical criteria for detecting IA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of clinical criteria for detecting IA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean WOMAC pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean WOMAC physical function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean global rating of disease
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Residual accommodation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uncorrected visual acuity at 40 cm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average time to the first recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Total recurrences
Endpoint domain: Mortality/survival
Primary endpoint: Local Control (LC) rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Barthel Index (MBI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: job tenure
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Reduction in dose exposure from contraceptive
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Follicle growth and probable ovulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Brachial artery flow‐mediated dilatation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: QoL-psychosocial total score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Total time from medical contact to balloon inflation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Door-to-balloon time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fasting ORAC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urinary 8‐epi PGF(2alpha)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Global improvement in pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in overall well being
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: CMBS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: S‐TxB2 concentrations above 0.72 ng/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VerifyNow Aspirin Reaction Units (ARU) ≥ 550
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: appreciation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased driving after drinking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of wound hematoma
Endpoint domain: Adverse events/effects
Primary endpoint: Coronary Heart Disease Risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: End-Stage Renal Disease Risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Knowledge of BLS Guidelines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of the Disease Activity Index to > or =4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall survival rate at 5 years
Endpoint domain: Mortality/survival
Primary endpoint: cause-specific survival rate at 5 years
Endpoint domain: Mortality/survival
Primary endpoint: Adequately controlled menorrhagia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with surgery results
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pain
Primary endpoint: Overall satisfaction with the procedure
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of repetitions performed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in total American Urological Association symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in residual urine volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interobserver agreement of prostate bed delineation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LDL-C levels < 160 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Propofol requirement for LMA insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean NRS‐11 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean STS (Symptom Severity Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mental health functioning
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: binge rates
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cumulative incidence of fractures
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment Escalation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: days alive without organ support by day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: team members' involvement in trials
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: confidence in communication about RCTs
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: awareness of different aspects of trial management
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: 24-h quit period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of heart failure (HF) requiring hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Recovery index (RI75)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overweight/obesity rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: patient survival prediction accuracy
Endpoint domain: Mortality/survival
Primary endpoint: treated uterine atony
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Total score of PANSS scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to wean off the devices and oxygen support
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Physician trust
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: stone free status at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Grade 3 or 4 Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Scar area of the wound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duodeno-jejunal motor response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: sigmoid motor response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: CPTPS frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total NDI scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in discomfort, burning, fullness after eating, and burping
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in parasympathetic nervous activities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Increase in feelings of comfort and naturalness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Intracranial pressure >30 mm Hg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depression scores of SDP mothers
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Physical well-being of the baby
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of NXY-059
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetics of NXY-059
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feelings of exhaustion
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Risk of new coronary event
Endpoint domain: Mortality/survival
Primary endpoint: Global hand function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activated hepatic stellate cells count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Increase in bucco-lingual width of KM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean surgery time
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Brain-derived neurotrophic factor serum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Active range of abduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Active range of flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Active range of internal rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VZV-specific cell-mediated immunity (CMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 24h ambulatory blood pressure levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: percentage of patients displaying normal 24h systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Endoscopic duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Need for second-look endoscopy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Clear stomach
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neurological outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Documentation rate of clinical interventions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: beta‐carotene concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: alpha‐tocopherol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Anti-inflammatory efficacy of PoCo
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Disc recapture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration time curve (AUC0‐24 h) of moclobemide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration time curve (AUC0‐24 h) of temazepam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak plasma concentration (Cmax) of moclobemide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak plasma concentration (Cmax) of temazepam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Inflammatory cell infiltration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Tcore
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PPO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total number of steps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psoriasis Area Severity Index score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dermatology Life Quality Index score decrease
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: fistula failure rate
Endpoint domain: Mortality/survival
Primary endpoint: venous diameter improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: P o (2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sao (2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction in number of health risks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: amount of graft integrated into newly formed bone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ease of use of FT compared to IL
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Confidence in correct dosing
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: General handling of FT compared to IL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diabetes knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of successful cannulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of successful cannulations on first attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time to complete cannulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Maximum plasma levobupivacaine concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes